A theme covering developments across the pharmaceutical market during infectious disease outbreaks, including the development, vaccination and supply discussions surrounding novel coronavirus treatments and vaccines. It focuses on external development and supply trends as market conditions, rather than the clinical development of specific candidates by the company.